Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;43:1214-1220
doi: 10.1161/01.HYP.0000126186.29571.41
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sata, M.
Right arrow Articles by Nagai, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sata, M.
Right arrow Articles by Nagai, R.
Related Collections
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Pathophysiology
Right arrow Lipid and lipoprotein metabolism

(Hypertension. 2004;43:1214.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Statins Augment Collateral Growth in Response to Ischemia but They Do Not Promote Cancer and Atherosclerosis

Masataka Sata; Hiroaki Nishimatsu; Jun-ichi Osuga; Kimie Tanaka; Nobukazu Ishizaka; Shun Ishibashi; Yasunobu Hirata; Ryozo Nagai

From the Departments of Cardiovascular Medicine (M.S., K.T., N.I.,Y.H, R.N.), Urology (H.N.), Metabolic Diseases (J.O., S.I.), University of Tokyo Graduate School of Medicine, Japan; Division of Endocrinology and Metabolism (S.I.), Department of Medicine, Jichi Medical School, Tochigi, Japan; and PRESTO (M.S.), Japan Science and Technology Agency, Kawaguchi, Saitama, Japan.

Correspondence to Dr Masataka Sata, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail msata-circ{at}umin.ac.jp

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, are widely prescribed to lower cholesterol. Recent reports suggest that statins may promote angiogenesis in ischemic tissues. It remains to be elucidated whether statins potentially enhance unfavorable angiogenesis associated with tumor and atherosclerosis. Here, we induced hind limb ischemia in wild-type mice by resecting the right femoral artery and subsequently inoculated cancer cells in the same animal. Cerivastatin enhanced blood flow recovery in the ischemic hind limb as determined by laser Doppler imaging, whereas tumor growth was significantly retarded. Cerivastatin did not affect capillary density in tumors. Cerivastatin, pitavastatin, and fluvastatin inhibited atherosclerotic lesion progression in apolipoprotein E-deficient mice, whereas they augmented blood flow recovery and capillary formation in ischemic hind limb. Low-dose statins were more effective than high-dose statins in both augmentation of collateral flow recovery and inhibition of atherosclerosis. These results suggest that statins may not promote the development of cancer and atherosclerosis at the doses that augment collateral flow growth in ischemic tissues.


Key Words: cholesterol • atherosclerosis • nitric oxide • circulation




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Kubo, K. Egashira, T. Inoue, J.-i. Koga, S. Oda, L. Chen, K. Nakano, T. Matoba, Y. Kawashima, K. Hara, et al.
Therapeutic Neovascularization by Nanotechnology-Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium
Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 796 - 801.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Fukuda, M. Sata, N. Ishizaka, and R. Nagai
Critical Role of Bone Marrow Angiotensin II Type 1 Receptor in the Pathogenesis of Atherosclerosis in Apolipoprotein E Deficient Mice
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Shimamura, N. Sato, M. Sata, H. Kurinami, D. Takeuchi, K. Wakayama, T. Hayashi, H. Iida, and R. Morishita
Delayed Postischemic Treatment With Fluvastatin Improved Cognitive Impairment After Stroke in Rats
Stroke, December 1, 2007; 38(12): 3251 - 3258.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Birnbaum, Y. Lin, Y. Ye, J. D. Martinez, M.-H. Huang, C. Y. Lui, J. R Perez-Polo, and B. F. Uretsky
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2891 - H2897.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. D. Kolodgie, J. Narula, C. Yuan, A. P. Burke, A. V. Finn, and R. Virmani
Elimination of Neoangiogenesis for Plaque Stabilization: Is There a Role for Local Drug Therapy?
J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2093 - 2101.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. R. Chade, X. Zhu, O. P. Mushin, C. Napoli, A. Lerman, and L. O. Lerman
Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia
FASEB J, August 1, 2006; 20(10): 1706 - 1708.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. K. Liao
Statin Therapy: Having the Good Without the Bad
Hypertension, June 1, 2004; 43(6): 1171 - 1172.
[Full Text] [PDF]